PLX-4720

Catalog No.S1152

Molecular Weight(MW): 413.83

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Cited by 110 Publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Nature, 2017, 548(7667):343-346

PubMed: 28792927 ( click the link to review the publication )

Nature, 2015, 517(7536):583-8

PubMed: 25494202 ( click the link to review the publication )

Cell, 2015, 160(1-2):161-76

PubMed: 25594179 ( click the link to review the publication )

Cell, 2015, 160(1-2):161-76

PubMed: 25594179 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(7):816-27

PubMed: 24771846 ( click the link to review the publication )

Nature, 2013, 498(7452):109-12

PubMed: 23685455 ( click the link to review the publication )

Nat Biotechnol, 2013, 31(7):630-7

PubMed: 23811600 ( click the link to review the publication )

Cell, 2013, 154(5):1036-46

PubMed: 23993095 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, S1097-2765(19)30838-X

PubMed: 31836388 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5232

PubMed: 31745079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5167

PubMed: 31727888 ( click the link to review the publication )

Cell Syst, 2019, 9(4):366-374

PubMed: 31521607 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )

Oncogene, 2019, 38(22):4384-4396

PubMed: 30710146 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(12):2506-2516

PubMed: 31229500 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31083627 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )
Mol Oncol, 2019, 13(2):480-494

PubMed: 30582770 ( click the link to review the publication )

Mol Cell Proteomics, 2019, 18(6):1096-1109

PubMed: 30890564 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(7):1426-1435

PubMed: 31063355 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):932-950

PubMed: 31096110 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Genes Genomics, 2019, 41(11):1273-1280

PubMed: 31388978 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1482

PubMed: 29662054 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Genome Res, 2018, 28(9):1353-1363

PubMed: 30061114 ( click the link to review the publication )

J Control Release, 2018, 277:48-56

PubMed: 29550398 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10902

PubMed: 30026510 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Med Sci (Basel), 2018, 6(1)

PubMed: 29304009 ( click the link to review the publication )

Biophys J, 2018, 114(6):1499-1511

PubMed: 29590606 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(2):219-237

PubMed: 27974353 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3953-3965

PubMed: 28096271 ( click the link to review the publication )

Oncogene, 2017, 36(32):4585-4596

PubMed: 28368422 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )

Neoplasia, 2017, 19(11):932-940

PubMed: 28963969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2017, 154:350-356

PubMed: 28365424 ( click the link to review the publication )
Cancer Res Treat, 2017, 49(4):947-959

PubMed: 28052651 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115140-115152

PubMed: 29383148 ( click the link to review the publication )

Cell Rep, 2016, 10.1016/j.celrep.2016.05.064

PubMed: 27320919 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Oncogene, 2016, 35(20):2675-80

PubMed: 26119932 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2876-2888

PubMed: 27571413 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(20):2612-25

PubMed: 27503857 ( click the link to review the publication )

Pharm Biol, 2016, 54(4):732-9

PubMed: 26931349 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):81995-82012

PubMed: 27835901 ( click the link to review the publication )

Nat Struct Mol Biol, 2015, 22(1):37-43

PubMed: 25437913 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1652-64

PubMed: 25617424 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 10.1111/pcmr.12364

PubMed: 25728708 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Front Oncol, 2015, 10.3389/fonc.2015.00095

PubMed: ( click the link to review the publication )

Front Oncol, 2015, 5:95

PubMed: 26029660 ( click the link to review the publication )

J Cell Physiol, 2015, 10.1002/jcp.24888

PubMed: 25600161 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Biomol Ther (Seoul), 2015, 23(4):320-6

PubMed: 26157547 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(9):2410-23

PubMed: 24573550 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7079-89

PubMed: 25320010 ( click the link to review the publication )

Cancer Res, 2014, 74(15):4122-32

PubMed: 25035390 ( click the link to review the publication )

Mol Syst Biol, 2014, 10:772

PubMed: 25538140 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(9):1314-23

PubMed: 25061102 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(5):2598-608

PubMed: 24550330 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Toxicol Lett, 2014, 10.1111/cmi.12305

PubMed: 24779413 ( click the link to review the publication )

J Pharm Pharm Sci, 2014, 17(1):154-68

PubMed: 24735766 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87457

PubMed: 24475291 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101286

PubMed: 24983357 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(16):4383-91

PubMed: 23812671 ( click the link to review the publication )

Sci Signal, 2013, 6(281):ra51

PubMed: 23800469 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 27(1):124-33

PubMed: 24112705 ( click the link to review the publication )

Oncogenesis, 2013, 2:e44

PubMed: 23588493 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1530-41

PubMed: 24152792 ( click the link to review the publication )

Clin Endocrinol, 2013, 81(1):109-16

PubMed: 24382015 ( click the link to review the publication )

Transl Oncol, 2013, 6(4):470-81

PubMed: 23908690 ( click the link to review the publication )

Mol Cell Biochem, 2013, 372(1-2):65-74

PubMed: 22941213 ( click the link to review the publication )

J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 925:124-8

PubMed: 23537694 ( click the link to review the publication )
J Biomol Screen, 2013, 19(4):526-37

PubMed: 24361645 ( click the link to review the publication )

J Membr Biol, 2013, 247(2):137-45

PubMed: 24258620 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(12):3316-27

PubMed: 22553342 ( click the link to review the publication )

Genes Dev, 2012, 26(10):1055-69

PubMed: 22549727 ( click the link to review the publication )

Oncogene, 2012, 32(40):4836-44

PubMed: 23208503 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(11):2652-60

PubMed: 22718120 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Biol Chem, 2012, 287(1):91-104

PubMed: 22027819 ( click the link to review the publication )

Biochem J, 2012, 450(2):285-94

PubMed: 23234544 ( click the link to review the publication )

Oncotarget, 2012, 3(12):1688-99

PubMed: 23518796 ( click the link to review the publication )

Mol Biol Cell, 2011, 22(23):4647-56

PubMed: 21976697 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23235

PubMed: 21829721 ( click the link to review the publication )

PLoS One, 2011, 6(11):e26908

PubMed: 22125603 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

C-Raf-1 (Y340D/Y341D) ^[1] (Cell-free assay)	B-Raf (V600E) ^[1] (Cell-free assay)	BRK ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)
6.7 nM	13 nM	130 nM	160 nM

In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-Raf^V600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-Raf^V600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-Raf^V600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. ^[1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN⁺ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN^- cells to PLX-4720-induced apoptosis. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
DU-4475	NEDsRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnVTWM2OD1yLkC3OFU4KM7:TR?=	MkmyV2FPT0WU
EoL-1-cell	NYeyO\|FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDqTWM2OD1yLkG0NVY3KM7:TR?=	M3v1PHNCVkeHUh?=
C32	NUHxfWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:ycVRtUUN3ME2wMlE2OTNzIN88US=>	MXfTRW5ITVJ?
M14	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXHPZJKSzVyPUCuNlE4PTdizszN	M3vFWHNCVkeHUh?=
CP50-MEL-B	M1fJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfnbXFKSzVyPUCuNlk4QDRizszN	M{LCOXNCVkeHUh?=
A101D	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjVW25KSzVyPUCuN\|I2QDlizszN	M1f6[nNCVkeHUh?=
G-361	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjsPIRKSzVyPUCuN\|Q3OzdizszN	NYfVWHd6W0GQR1XS
HT-144	M3XaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;xfIVYUUN3ME2wMlM3OzJ7IN88US=>	MWXTRW5ITVJ?
ACN	NHrWO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rT[mlEPTB;MD6zPFQ4PyEQvF2=	M3K3[3NCVkeHUh?=
COLO-829	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwM{i5Olgh\|ryP	MWPTRW5ITVJ?
MEL-HO	NVHCcY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO5Z\|dkUUN3ME2wMlQyOTd7IN88US=>	MV3TRW5ITVJ?
SH-4	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWe2RlZbUUN3ME2wMlQyPDJ{IN88US=>	M1zkc3NCVkeHUh?=
SK-MEL-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXqTWM2OD1yLkWxOVY5KM7:TR?=	M4OxXHNCVkeHUh?=
A375	NIjvWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\2bWJkUUN3ME2wMlY4OzV7IN88US=>	NFf6[YlUSU6JRWK=
MMAC-SF	NYjtT5llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOxcmtKSzVyPUCuOlg3OTRizszN	NH\jW2NUSU6JRWK=
BHT-101	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljyTWM2OD1yLkewO\|AzKM7:TR?=	M{PI[HNCVkeHUh?=
K5	M{\qbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7hTWM2OD1yLke2NVQ5KM7:TR?=	M2L5SHNCVkeHUh?=
BV-173	NInCO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPHTWM2OD1yLke5OlQ1KM7:TR?=	NWHjcYtyW0GQR1XS
RVH-421	NUnNUpptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3X1R2lEPTB;MD64Olc6PiEQvF2=	NVm5cXZNW0GQR1XS
HCC2218	NHPKRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nPZmlEPTB;MD64O\|g1PCEQvF2=	NVT0XFJ3W0GQR1XS
WM-115	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3OU\|hKSzVyPUCuPFg3QTJizszN	MnXZV2FPT0WU
SK-MEL-28	NGnhPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLLbXVjUUN3ME2xMlA1PTZ7IN88US=>	MnXXV2FPT0WU
COLO-679	M1LwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7zOoVKSzVyPUGuNVA1PjRizszN	NILvZWNUSU6JRWK=
MZ7-mel	M4PVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwMUS5OlMh\|ryP	M1PBT3NCVkeHUh?=
SK-MEL-30	NHvFVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYX3cGMzUUN3ME2xMlM{Ozh4IN88US=>	NGPvZ4JUSU6JRWK=
NCI-H209	NHnNfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljsTWM2OD1zLk[wPFYh\|ryP	M3HPSXNCVkeHUh?=
HTC-C3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrX[5pKSzVyPUGuOlYzQTRizszN	NG\BbmNUSU6JRWK=
KARPAS-45	NX7UfGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XueWlEPTB;Mj6wOFk4QCEQvF2=	M4O5e3NCVkeHUh?=
NCI-SNU-5	NFrldVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDZcI5KSzVyPUKuNVE6PjlizszN	NIKxe3BUSU6JRWK=
KP-4	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vCR2lEPTB;Mj6zNFc5PyEQvF2=	MmLVV2FPT0WU
PA-1	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJwN{K2O\|Mh\|ryP	Ml7OV2FPT0WU
HuO-3N1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX76WW5VUUN3ME2yMlg4QTR4IN88US=>	M{fVWnNCVkeHUh?=
NCI-H358	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XvVWlEPTB;Mj65NlI{OiEQvF2=	MYrTRW5ITVJ?
CTB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\pTWM2OD1\|LkSwNVc3KM7:TR?=	NXKxPVdCW0GQR1XS
697	M2KxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7TUIJ7UUN3ME2zMlU2OjZ4IN88US=>	MXXTRW5ITVJ?
CP66-MEL	NX\rcJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\ZTWM2OD12LkG1PVI4KM7:TR?=	NX\TNGJFW0GQR1XS
NB13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\lO\|lIUUN3ME20MlQ6OTd7IN88US=>	MnTKV2FPT0WU
DBTRG-05MG	M3fjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorlTWM2OD12LkWzN\|I2KM7:TR?=	MX\TRW5ITVJ?
A2058	NIDPelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvRTXV1UUN3ME20MlczOTZ2IN88US=>	NH7lUlFUSU6JRWK=
KG-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITqZ5RKSzVyPUSuO\|M6ODhizszN	NYfYXXQyW0GQR1XS
8305C	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTVwMUi3N{DPxE1?	MVjTRW5ITVJ?
RPMI-7951	NXzIUW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrlZ4VMUUN3ME21MlgxOjh\|IN88US=>	MYXTRW5ITVJ?
CHL-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHES4R1UUN3ME21Mlk4PjB\|IN88US=>	NUfuPYFCW0GQR1XS
TI-73	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS5NZZKSzVyPU[uNFA6ODJizszN	M2LF[XNCVkeHUh?=
HT-1080	M{XGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULhbnBkUUN3ME22MlExQTR4IN88US=>	MVLTRW5ITVJ?
ES5	NGC4UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnoTWM2OD14LkG0PVI1KM7:TR?=	NWHDVoJNW0GQR1XS
8-MG-BA	NG[4bJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzFTWM2OD14LkG4NVI6KM7:TR?=	M2q1fnNCVkeHUh?=
NB7	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXGO5p2UUN3ME22MlIyOzd\|IN88US=>	NF24e41USU6JRWK=
H4	M4jvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHxc\|dHUUN3ME22MlIzPDl\|IN88US=>	NXL6fZpHW0GQR1XS
CAL-72	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\CNWlEPTB;Nj60OVQzOyEQvF2=	M2nwTHNCVkeHUh?=
HCC1806	NVTpNYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\MTWM2OD14LkixPVMyKM7:TR?=	MkfvV2FPT0WU
BCPAP	MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\OeFNqUUN3ME23MlIyPzZ2IN88US=>	MYLTRW5ITVJ?
LB2241-RCC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofBTWM2OD15LkO2PVA4KM7:TR?=	MYfTRW5ITVJ?
COLO-741	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\tPJJKSzVyPUiuNFE3PzlizszN	NHTD[IJUSU6JRWK=
HSC-3	NWnXPYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nQUmlEPTB;OD6wO\|A3QCEQvF2=	NFTBb4FUSU6JRWK=
SW982	NEfjZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\0c25qUUN3ME24MlQyPTF4IN88US=>	NY\oPZdRW0GQR1XS
GCT	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3aTWM2OD16Lke1N\|E1KM7:TR?=	MmPqV2FPT0WU
KY821	NXLoSIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEi4T2tKSzVyPUmuNFUyPzhizszN	MWLTRW5ITVJ?
JVM-3	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYX6UnR7UUN3ME25MlU3QTl7IN88US=>	NEDse4NUSU6JRWK=
RS4-11	NHPvc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfidoxKSzVyPUmuOlA1QCEQvF2=	NVXLfolTW0GQR1XS
VA-ES-BJ	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFyLkCxOFkh\|ryP	NH\C[XFUSU6JRWK=
A431	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHT2R\|lKSzVyPUGwMlQzOTJizszN	NFviU\|hUSU6JRWK=
LXF-289	Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nSb2lEPTB;MUCuOFU5KM7:TR?=	M17LeHNCVkeHUh?=
SK-MEL-24	NF\vZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7lTWM2OD1zMD64Nlc1KM7:TR?=	NEH5W3dUSU6JRWK=
NOS-1	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoriTWM2OD1zMD64OFczKM7:TR?=	NFPKdY5USU6JRWK=
KNS-62	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jvT2lEPTB;MUGuNlQxPCEQvF2=	NXnTc5UzW0GQR1XS
SK-HEP-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTSUJNKSzVyPUGxMlM2OjdizszN	NUjTdFlVW0GQR1XS
A3-KAW	NFy1UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTFzLkexO\|gh\|ryP	MUnTRW5ITVJ?
SK-LU-1	NWPkTIliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTF{LkK2OVUh\|ryP	NFL2ZlBUSU6JRWK=
TYK-nu	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrTO2w4UUN3ME2xNk4{QTN{IN88US=>	NH;BfI9USU6JRWK=
NMC-G1	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XycWlEPTB;MUKuOlA3OiEQvF2=	NIOzfoFUSU6JRWK=
BB65-RCC	NYPXOldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHySlRKSzVyPUGyMlcyPjlizszN	MUHTRW5ITVJ?
QIMR-WIL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVK2TohTUUN3ME2xNk45QDN\|IN88US=>	NFHkOXhUSU6JRWK=
D-566MG	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFqwR5BKSzVyPUGzMlk2PzZizszN	NWS4dodNW0GQR1XS
KYSE-140	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXuS4p1UUN3ME2xOE4xPzV\|IN88US=>	NHrlUYVUSU6JRWK=
SCC-4	NV3mO2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPWTWM2OD1zND6zN\|U6KM7:TR?=	MoPDV2FPT0WU
U251	NVLCWo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j2NWlEPTB;MUSuPFQ6OiEQvF2=	MXzTRW5ITVJ?
D-542MG	M1TXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmP1TWM2OD1zND65NlIzKM7:TR?=	M172NnNCVkeHUh?=
LAMA-84	NEDXUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTBVoJuUUN3ME2xOE46QTN{IN88US=>	MnzYV2FPT0WU
NCI-H720	NEfOTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOxTWM2OD1zNT6yOlg1KM7:TR?=	MWLTRW5ITVJ?
DEL	M3W2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDleXFHUUN3ME2xOU41Ojl\|IN88US=>	MXjTRW5ITVJ?
SBC-1	NYnqWmlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF3LkSzNFUh\|ryP	Mln2V2FPT0WU
ECC10	M33qWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfxcY1KSzVyPUG1MlQ1PThizszN	NHfFTo1USU6JRWK=
Daoy	NWnOeGRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3vTWM2OD1zNT63OlE3KM7:TR?=	M2XlcXNCVkeHUh?=
SCH	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVGwPJlMUUN3ME2xOU44QDN3IN88US=>	MYTTRW5ITVJ?
MZ2-MEL	NYXUT\|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TxeWlEPTB;MU[uNFY1PiEQvF2=	M{O5NnNCVkeHUh?=
CAL-12T	NXvMVIl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTF4LkS4OlIh\|ryP	M1ywOHNCVkeHUh?=
KE-37	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnadY5KSzVyPUG2MlgyODdizszN	M1jVcnNCVkeHUh?=
LS-411N	NYLYOZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO2dmN5UUN3ME2xO{4yOThizszN	NFP5V5hUSU6JRWK=
NCI-H2228	NUHkVIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrOTFVKSzVyPUG3MlMxPzFizszN	NFn0VpFUSU6JRWK=
SK-MEL-2	MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4G1dWlEPTB;MUeuOFk3PSEQvF2=	M4\Bd3NCVkeHUh?=
HN	NH:zdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTF5LkeyOFgh\|ryP	Ml\TV2FPT0WU
NCI-H1648	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[4WGlEPTB;MUeuPFE5KM7:TR?=	MYDTRW5ITVJ?
IA-LM	NF;N[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDoS4RvUUN3ME2xPE4{OTd{IN88US=>	M4\hUHNCVkeHUh?=
EW-13	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;UTWM2OD1zOD61O\|A5KM7:TR?=	M2joWHNCVkeHUh?=
YKG-1	NUP3SZh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF7LkW3NVEh\|ryP	NWPSZ5R[W0GQR1XS
KNS-81-FD	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O2PGlEPTB;MUmuOVg2QCEQvF2=	NUH4S2hqW0GQR1XS
23132-87	NYfrSYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\CNXRKSzVyPUG5Mlc3PDJizszN	MVrTRW5ITVJ?
NUGC-3	NVPJNI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O4SmlEPTB;MUmuPVg5PyEQvF2=	NGH5R41USU6JRWK=
5637	NVfVN45rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnrb5Z6UUN3ME2yNE4xPDd6IN88US=>	NWG4TWpSW0GQR1XS
NCI-H1755	NVTTXGpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln5TWM2OD1{MD60O\|Y1KM7:TR?=	MoDXV2FPT0WU
RH-18	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;LXll{UUN3ME2yNE42PzR6IN88US=>	NHr6dZhUSU6JRWK=
RXF393	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHDU2RmUUN3ME2yNE43PzV4IN88US=>	M2HKUXNCVkeHUh?=
LU-134-A	NY\lOphyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDUTWM2OD1{MD63NFU3KM7:TR?=	M4e0bnNCVkeHUh?=
TE-12	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEm4PIRKSzVyPUKwMlczODFizszN	NWHUUIZ1W0GQR1XS
MOLT-4	NHPUS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPU[lZKSzVyPUKxMlE6OTVizszN	M2i4NHNCVkeHUh?=
IGR-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PoT2lEPTB;MkGuN\|c6PiEQvF2=	Mm\6V2FPT0WU
HOP-92	NYDNR2NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJzLkS5PFch\|ryP	MoLCV2FPT0WU
SK-MES-1	NFrqV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTJzLkezPFEh\|ryP	NX\zbWY3W0GQR1XS
LU-65	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTJzLki2NlQh\|ryP	M2HzXHNCVkeHUh?=
MS-1	NFLGR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP2[mJKSzVyPUKyMlEzODNizszN	NX7GWmpDW0GQR1XS
LoVo	M3m3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ{LkK0OEDPxE1?	NYO0bHJ2W0GQR1XS
A704	NGPJR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHSNYQ2UUN3ME2yNk42OTV3IN88US=>	NYfOWWVQW0GQR1XS
HT-1376	NXe4N2JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\STWM2OD1{Mj62NFU6KM7:TR?=	MV\TRW5ITVJ?
IST-MEL1	M3jK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFntVm9KSzVyPUKyMlY4PTFizszN	NIDDS4RUSU6JRWK=
Ramos-2G6-4C10	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPZ[IpKSzVyPUKyMlc{PjZizszN	M3\x[XNCVkeHUh?=
T47D	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD3Xo1kUUN3ME2yNk44QTd7IN88US=>	MlvjV2FPT0WU
HT-1197	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LB[WlEPTB;MkOuNFgyPyEQvF2=	NGe3enVUSU6JRWK=
LB2518-MEL	NH;SVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1WzeGlEPTB;MkOuOlQyOiEQvF2=	NV\tdJA2W0GQR1XS
J-RT3-T3-5	M2rW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHxS41QUUN3ME2yOE44PTl3IN88US=>	MXPTRW5ITVJ?
SK-NEP-1	M3vUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWOxeotGUUN3ME2yOE45PzR2IN88US=>	MnjxV2FPT0WU
NCI-H526	NEDZ[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTJ3LkCwNlMh\|ryP	MnXOV2FPT0WU
IST-SL1	NHXRU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzTTWM2OD1{NT6yO\|UyKM7:TR?=	Mn72V2FPT0WU
HH	NV;5O5dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfvUYpsUUN3ME2yOU4{OTl{IN88US=>	MoTIV2FPT0WU
NCI-H82	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:5TWM2OD1{NT65N\|gh\|ryP	MVvTRW5ITVJ?
SNU-449	NIW4eodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HPXmlEPTB;MkeuNlAyQCEQvF2=	NYnuR4g{W0GQR1XS
COR-L23	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnWcYhKSzVyPUK3MlI5OTNizszN	M37GTXNCVkeHUh?=
LOXIMVI	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37sNWlEPTB;MkeuN\|Y5KM7:TR?=	MXTTRW5ITVJ?
GR-ST	NInxUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTJ5Lk[3NFYh\|ryP	MXnTRW5ITVJ?
NCI-SNU-1	M{HQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDZTWM2OD1{Nz65OFQh\|ryP	MmTUV2FPT0WU
ALL-PO	M4fCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJ6LkG2NFQh\|ryP	NX70TWpIW0GQR1XS
ML-2	NFvSZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYS5ZXBpUUN3ME2yPE4zQDF2IN88US=>	M3fIdHNCVkeHUh?=
HOP-62	M2DTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYKzZVU1UUN3ME2yPE44OTNizszN	MU\TRW5ITVJ?
EGI-1	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X1PGlEPTB;MkiuPFg1PSEQvF2=	NIm0ZZdUSU6JRWK=
TCCSUP	NXizUZRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\HWWlEPTB;MkiuPVI4OiEQvF2=	NXvvV3lbW0GQR1XS
LB996-RCC	NG[0bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF23NmtKSzVyPUK5MlU3QDJizszN	MoDIV2FPT0WU
LCLC-97TM1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf6TWM2OD1\|Mj6xPVY1KM7:TR?=	NH;IXINUSU6JRWK=
NCI-H1304	M4fNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknzTWM2OD1\|Mj6zN\|AyKM7:TR?=	MX\TRW5ITVJ?
KP-N-YS	NGS0[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTN{LkW5O\|Mh\|ryP	M1eyR3NCVkeHUh?=
NCI-H1770	NFvKcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jG[WlEPTB;M{OuNVY1QCEQvF2=	NWDydoZVW0GQR1XS
EM-2	NF6wN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL0TWM2OD1\|Mz62OVA1KM7:TR?=	MYHTRW5ITVJ?
ChaGo-K-1	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XNZ2lEPTB;M{OuO\|I{PiEQvF2=	MXTTRW5ITVJ?
ACHN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzVTWM2OD1\|Mz64N\|g2KM7:TR?=	MmX5V2FPT0WU
MN-60	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfZSmNKSzVyPUOzMlg2PDRizszN	NIq4clBUSU6JRWK=
EW-18	M4TjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2njfmlEPTB;M{OuPFk4OSEQvF2=	NVjSNok2W0GQR1XS
KGN	NFe2WndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG0WINKSzVyPUO1MlczQTJizszN	NFe2ZpBUSU6JRWK=
U031	NWXybHNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTN3LkixN\|Ih\|ryP	M1H0VHNCVkeHUh?=
HMV-II	M2\B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO0eGw3UUN3ME2zOk4xPzd2IN88US=>	MYfTRW5ITVJ?
L-363	NXfIZmhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3UN3RKSzVyPUO3MlY1PTVizszN	NYrCR4ZqW0GQR1XS
NCI-H1155	NFLWfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTN6LkCwNVUh\|ryP	M3vYPHNCVkeHUh?=
NCI-H1793	NISyXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTN6LkGwNlYh\|ryP	M3LoW3NCVkeHUh?=
P30-OHK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTN6LkGzN\|Ih\|ryP	M{PqbXNCVkeHUh?=
AN3-CA	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DDOGlEPTB;M{iuNVYyPSEQvF2=	M4f2e3NCVkeHUh?=
UACC-257	NUTuXlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nYdGlEPTB;M{iuO\|kh\|ryP	NYGzWoJSW0GQR1XS
MCF7	NH3TTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXiTWM2OD1\|OT64OlI6KM7:TR?=	M{\oeHNCVkeHUh?=
KP-N-YN	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTRyLkSyPFUh\|ryP	MXTTRW5ITVJ?
T98G	NE[xd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP3eY5KSzVyPUSwMlQ6PTdizszN	MnPNV2FPT0WU
HGC-27	NXPodYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTR\|LkK3OEDPxE1?	NXzMPIpiW0GQR1XS
NCI-H1092	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYK2XVdLUUN3ME20N{4zQDl3IN88US=>	M1;FRnNCVkeHUh?=
KARPAS-299	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYL0NY5xUUN3ME20N{4{ODdzIN88US=>	NWjifox4W0GQR1XS
LB1047-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLaTWM2OD12ND65PVU6KM7:TR?=	MnHHV2FPT0WU
786-0	NV\MXnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Gyb2lEPTB;NEWuOlUh\|ryP	MWDTRW5ITVJ?
HCC2157	NXjme2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3kdY9KSzVyPUS2MlA{PTlizszN	NFywSGRUSU6JRWK=
NY	NWnP[nNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTR4LkG3O\|gh\|ryP	NVzwc\|hjW0GQR1XS
EFM-19	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTR[GNGUUN3ME20Ok44PTN\|IN88US=>	MXjTRW5ITVJ?
EW-16	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M163bGlEPTB;NE[uO\|gxPiEQvF2=	MXPTRW5ITVJ?
UM-UC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnTZVlKSzVyPUS2MlgxPTlizszN	MlHCV2FPT0WU
HT-29	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;uTWM2OD12Nz64O\|kzKM7:TR?=	MVLTRW5ITVJ?
LN-405	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TjdmlEPTB;NEiuNFgzPyEQvF2=	NXn0eok1W0GQR1XS
NCI-H727	M{j0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTR6Lke3NlYh\|ryP	NUT5WXVNW0GQR1XS
D-502MG	NVuxeoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHNWWtKSzVyPUS4Mlk3PzZizszN	NHPJW2RUSU6JRWK=
GMS-10	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj6TWM2OD12OT6yPVc1KM7:TR?=	NHnBTIFUSU6JRWK=
MEL-JUSO	NXHpV\|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHnTWM2OD12OT6zOFch\|ryP	NUf5e5RsW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-MEK / MEK / p-ERK / ERK / p-FAK(S910); PubMed: 23076151 J Biol Chem WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK. p-EGFR 1173 / EGFR / p-Akt / Akt; PubMed: 26023796 Oncotarget Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272. p27 / Cyclin D1 / pRb; PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels. pAkt(Ser473) / pAkt(Thr308); PubMed: 21828154 Invest Ophthalmol Vis Sci Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.	23076151 26023796 21828154
Immunofluorescence	LAMP1; PubMed: 30979895 Nat Commun Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. ZKSCAN3 / TFEB ; PubMed: 30979895 Nat Commun Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments.	30979895
Growth inhibition assay	Cell viability; PubMed: 27848137 J Neurooncol AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.	27848137
ELISA	mIFN-γ; PubMed: 23204132 Clin Cancer Res (C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (P<0.05, * P<0.01) Data are representative of 3 independent experiments.	23204132

In vivo

Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-Raf^V600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-Raf^V600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. ^[1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. ^[3]

Protocol

Kinase Assay:^[1]	- Collapse In vitro Raf kinase activities: The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl₂, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:^[1]	- Collapse Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells Concentrations: Dissolved in DMSO, final concentrations ~1 mM Incubation Time: 24, 48, and 72 hours Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells Formulation: Suspended in vehicle (5% DMSO, 1% methylcellulose) Dosages: 5, 20, or 100 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+50% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PLX-4720 SDF

Molecular Weight	413.83
Formula	C₁₇H₁₄ClF₂N₃O₃S
CAS No.	918505-84-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What would you recommend to make working solution for intraperitoneal injection into mice?
Answer:
PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

PLX-4720

Cited by 110 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PLX-4720 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Choose Your Country or Region

By Signaling Pathways

By product type

PLX-4720

Cited by 110 Publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PLX-4720 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)